<DOC>
	<DOCNO>NCT02620150</DOCNO>
	<brief_summary>This 10 week , double-blind , placebo control trial evaluate SSRI ( Selective Serotonin Reuptake Inhibitor ) effect treatment depression HIV/AIDS focus innate immunity inflammation . Depressed population HIV + cART , currently treatment depression . Subjects complete cognitive behavior therapy , CCBT depression . Blood sample collect virologic , neuroendocrine , immunologic evaluation . Our overarch hypothesis SSRI treatment depression improvement depressive symptom lead increased innate immunity decrease inflammation , result good control HIV disease decrease morbidity .</brief_summary>
	<brief_title>SSRI Effects Depression Immunity HIV/AIDS</brief_title>
	<detailed_description>To pursue long-term objective successfully treat co-morbid mental medical disorder HIV/AIDS , study aim determine whether : 1 ) SSRI treatment significantly increase innate immunity decrease chronic inflammation immune activation , 2 ) change depressive symptom correlate change immunity HIV/AIDS . HIV-seropositive , depressed subject randomize 10 week double blind therapy either escitalopram placebo . All participant concurrently begin CCBT ( Computerized Cognitive Behavioral Therapy ) use program Good Days Ahead . Subject visit occur weekly first 6 week week 8 10 . The treat clinician assess side effect , review symptomatic progress , adjust study medication clinically appropriate . An independent clinical evaluator ass patient baseline , week 1-6 , 8 10 . Blood sample collect baseline week 2 , 4 , 10 use assay marker innate immune suppression ( lytic unit NK cell , LUNK , intracellular IFN gamma NK cell ) marker inflammation ( IL-6 C-Reactive Protein ) . At end 10-week treatment phase , participant refer appropriate clinical treatment depression .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>1 . Men woman age 1864 year , race ethnicity , 2 . HIVseropositive ELISA Western Blot assay , infected behavioral transmission ( perinatal HIV exclude ) , 3 . Willing able comply antidepressant medication regimen schedule followup visit , 4 . Currently document regimen cART least 3 month Viral load le 40 copies/ml , 5 . Current depressive symptom ( HAMD17 score equal great 13 ) , SCID diagnosis Major Depressive Disorder , 6 . Able understand provide inform consent . 1 . Acute mark suicidal ideation intent , 2 . Significant cognitive impairment dementia , 3 . Use medication know alter immune function within 4 week prior enrollment , 4 . Immunization HIV vaccine , 5 . Presence psychotic symptom know diagnosis primary psychotic disorder , 6 . Currently take antipsychotic medication , 7 . Pregnant within nine month postdelivery , lactation , 8 . Current chronic medical condition would likely preclude adherence protocol completion trial , 9 . History bipolar disorder ( I II ) schizophrenia , 10 . Current pharmacotherapy and/or psychotherapy treatment depression , 11 . A history intolerance nonresponse adequate trial escitalopram ( SSRIs ) , 12 . Renal failure , include require dialysis , 13 . Taking diuretic , 14 . History seizure take Carbamazepine , 15 . Taken MAOIs within 14 day , 16 . On antibiotic Linezolid take IV methylene blue , 17 . On regular regime medication know anticoagulant property NSAID , aspirin warfarin , 18 . A history acute narrow/closed angle glaucoma , 19 . Currently take CNS drug , 20 . On triptan medication , 21 . Undergoing ECT .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>Depression</keyword>
	<keyword>SSRI</keyword>
	<keyword>Escitalopram</keyword>
	<keyword>Immunity</keyword>
</DOC>